Forgot Password?
Return to Course Listing

CME: Insomnia: Updates from SLEEP 2022, (the 36th annual meeting of the APSS)


Activity Description / Statement of Need:

In this online, self-learning activity:

Insomnia is characterized by the dissatisfaction of sleep quality or quantity characterized by having difficulty falling asleep, staying asleep, waking too early, or a combination of these. It is the most common general complaint in medical practice, and it is designated chronic if the condition persists for three months, despite the opportunity for sleep or eradication of external stimulus.Insomnia affects people of all ages, though the likelihood of developing insomnia increases with age: one-third of the adult population reports having been affected by at least one symptom of insomnia. Several factors may contribute to the condition. Poor sleep may develop spontaneously, be influenced by genetics, occur in response to stress or other psychological triggers, arise due to endogenous neurochemical dysregulation, or a combination of any of those factors. Insomnia puts patients at a higher risk of developing mood disorders such as anxiety and depression, and cardiovascular disease. The condition is liable for patients spending $2,000 per year and the U.S. $63 billion annually, encompassing the cost of reduced productivity – including absences, work-related accidents, and health care resources.

Target Audience:

The following HCPs: neurologists, psychiatrists, sleep medicine specialists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with chronic insomnia.

Commercial Support Disclosure: This program is supported by an educational grant from Eisai.

This activity is free of charge.

Release Date: September 29, 2022 -- Expiration Date: September 29, 2023

Faculty: Alon Avidan, M.D., MPH, FAASM, FAAN


  • Faculty member introduction, disclosures
  • Overview of insomnia
  • Major findings from SLEEP 2022, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice
  • Concluding remarks

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the definitions and pathophysiology of insomnia, approach to the assessment, and differential diagnosis of insomnia.
  • Explain the role of insomnia comorbidities, especially psychiatric comorbidities, in perpetuating chronic insomnia.
  • Review the key hypnotic agents and their mechanisms of action and apply that information to a patient case.
  • Describe the role of the new dual orexin receptor antagonist in the management of chronic insomnia.
  • Employ the American Academy of Sleep Medicine practice guidelines on managing insomnia in a treatment plan,


ACCME Activity #202339448


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Alon Y. Avidan, MD, MPH, Professor of Neurology, UCLA, Director, UCLA Sleep Disorders Center, has received financial compensation from: Takeda, Avade,Harmony, Merck, and Eisai for consulting and/or speaker's bureau work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Eisai.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Contemporary challenges and updates and in the diagnosis and management of Alzheimer’s disease – from early disease onward

Saving lives: New paradigms of care for opioid use disorder (OUD)

Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies